Response: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).
作者信息
Choe EunYeong, Kang Eun Seok
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, International St. Mary's Hospital, Incheon, Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Diabetes Metab J. 2014 Aug;38(4):319-20. doi: 10.4093/dmj.2014.38.4.319.
Abstract
摘要
相似文献
1
Response: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).
Diabetes Metab J. 2014 Aug;38(4):319-20. doi: 10.4093/dmj.2014.38.4.319.
2
Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).
Diabetes Metab J. 2014 Aug;38(4):317-8. doi: 10.4093/dmj.2014.38.4.317.
3
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).
Diabetes Metab J. 2021 Jul;45(4):615-616. doi: 10.4093/dmj.2021.0081. Epub 2021 Jul 30.
4
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).
Diabetes Metab J. 2021 Jul;45(4):619-620. doi: 10.4093/dmj.2021.0118. Epub 2021 Jul 30.
5
A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.
Medicine (Baltimore). 2016 Nov;95(44):e5155. doi: 10.1097/MD.0000000000005155.
6
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.
Diabetes Metab J. 2014 Jun;38(3):211-9. doi: 10.4093/dmj.2014.38.3.211. Epub 2014 Jun 17.
7
Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).
Diabetes Metab J. 2015 Oct;39(5):446-7. doi: 10.4093/dmj.2015.39.5.446. Epub 2015 Oct 22.
8
The Research Progress of DPP-4 Inhibitors.
Mini Rev Med Chem. 2020;20(17):1709-1718. doi: 10.2174/1389557520666200628032507.
9
Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus ( 2019;43:582-9).
Diabetes Metab J. 2019 Dec;43(6):915-916. doi: 10.4093/dmj.2019.0213.
10
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y.
本文引用的文献
1
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.
Diabetes Metab J. 2014 Jun;38(3):211-9. doi: 10.4093/dmj.2014.38.3.211. Epub 2014 Jun 17.
2
Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.
Clin Drug Investig. 2014 Jul;34(7):513-9. doi: 10.1007/s40261-014-0196-z.
3
DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Adv Ther. 2012 Jan;29(1):14-25. doi: 10.1007/s12325-011-0088-z. Epub 2011 Dec 22.
4
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Drugs. 2011 Jul 30;71(11):1441-67. doi: 10.2165/11591400-000000000-00000.
5
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Diabetes Obes Metab. 2011 Sep;13(9):775-83. doi: 10.1111/j.1463-1326.2011.01414.x.
6
Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.
J Endocrinol Invest. 2011 Jan;34(1):69-77. doi: 10.1007/BF03346698. Epub 2011 Jan 13.
7
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.
J Diabetes Sci Technol. 2009 Jan;3(1):68-82. doi: 10.1177/193229680900300108.
8
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.
Diabetologia. 2010 Mar;53(3):552-61. doi: 10.1007/s00125-009-1611-5. Epub 2009 Dec 3.
9
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
Nutr Metab Cardiovasc Dis. 2008 Nov;18(9):639-45. doi: 10.1016/j.numecd.2008.08.002. Epub 2008 Oct 11.
10
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care. 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703.
Zotero 插件